Deal Watch: United Therapeutics Looks To Extend PAH Dominance With Respira's Combo Product
Executive Summary
United will finance clinical development of drug/inhaler device combo with Respira. Takeda offloads more mature products to its joint venture with Teva, and signs a microbiome partnership with Finch Therapeutics.
You may also be interested in...
Finance Watch: Two New VC Funds Raise $755m To Fund Innovation
Private Company Edition: Also, Medicxi’s new €200m fund will be reinvested in a portfolio of six life science companies and Silverback more than doubled its 2020 money with an $85m series C round.
Ligand Adds New Expertise, Revenue Potential With Pfenex Buyout
Deal Snapshot: In acquiring its fellow San Diego firm for an estimated deal value of up to $516m, Ligand picks up protein-expression technology, revenue-driving partnerships and the potential for more.
Asia Deal Watch: Lupin Signs Up Three EU Marketing Partners For NaMuscla
Lupin links with Exeltis, Cresco and Macure to sell the NDM therapy in western and central Europe. Plus deals involving Cipla, GoApptiv, Takeda, Debiopharm, PharmaMar and TTY.